Research dossier
Clinical research on Arginine
8 trials reviewed across 5 indications.
Strongest evidence
Blood pressure & vascular support
Mechanism
Arginine is the substrate for endothelial nitric-oxide synthase; more arginine can mean more NO and vascular smooth-muscle relaxation. The bottleneck is delivery — much of an oral dose is destroyed by intestinal and hepatic arginase before reaching the bloodstream, which is why citrulline raises plasma arginine more efficiently.
Two meta-analyses converge: oral L-arginine (≥4 g/day) lowers systolic BP by ~5–6 mmHg and diastolic by ~2.6 mmHg, with the effect disappearing above ~9 g/day. Real but modest, and achievable at lower dose with citrulline.
Most useful as adjunct support in adults with elevated blood pressure. Not a replacement for antihypertensive medication. AVOID after a recent myocardial infarction (see safety).
Trials cited
L-arginine and blood pressure (dose-response meta-analysis)
positive · Meta-analysis
Shiraseb et al., 2022, Advances in Nutritionn=825Pooling 22 RCTs (n=825), oral L-arginine lowered systolic BP by ~6.4 mmHg (95% CI -8.74 to -4.05) and diastolic by ~2.6 mmHg. A clear dose-response existed up to ~9 g/day, above which the effect vanished. The diastolic effect was larger in women than men.
Small constituent trials and meaningful heterogeneity. The effect is a few mmHg — supportive of, not a substitute for, antihypertensive therapy. Note that citrulline achieves a comparable BP effect at lower doses with better tolerability.
L-arginine and blood pressure (meta-analysis of 11 RCTs)
positive · Meta-analysis
Dong et al., 2011, American Heart Journaln=387The earlier, widely cited BP meta-analysis. Pooling 11 double-blind placebo-controlled RCTs (n=387), oral L-arginine lowered systolic BP by ~5.39 mmHg (95% CI -8.54 to -2.25) and diastolic by ~2.66 mmHg (95% CI -3.77 to -1.54). Consistent in direction with the larger 2022 dose-response analysis.
Constituent trials were small and used a very wide dose range (4–24 g/day). Modest effect; replicated by Shiraseb 2022.
Pharmacokinetics of oral citrulline vs arginine on nitric oxide
mixed · RCT
Schwedhelm et al., 2008, British Journal of Clinical Pharmacologyn=20The pharmacokinetic study that reframes the whole arginine category. Counterintuitively, oral L-citrulline raised plasma L-arginine more effectively than oral L-arginine itself — because arginine is heavily degraded by intestinal arginase before absorption, while citrulline bypasses it and is converted to arginine in the kidney. Honest takeaway: if the goal is to raise arginine/NO, citrulline is the better-delivered molecule.
Biomarker endpoints in healthy volunteers, not clinical outcomes. The result is the central reason to question oral arginine as an NO delivery vehicle — see our L-citrulline dossier for the matching analysis.
Erectile function
Mechanism
Penile erection depends on nitric-oxide-driven vasodilation of the cavernosal arteries — the same pathway PDE-5 inhibitors target. Raising arginine/NO availability is a plausible upstream lever.
A meta-analysis of 3 RCTs (n=184) shows a meaningful IIEF improvement (~8.9 points) — but the benefit comes from arginine COMBINED with Pycnogenol, not arginine alone, and the trials cluster around the commercial Prelox product. Honest read: the combination helps mild ED; isolated high-dose arginine has thinner support and citrulline matched it in its own trial.
Evidence is for an arginine + Pycnogenol combination in MILD-to-moderate ED. Weaker than PDE-5 inhibitors; not validated for severe ED. Do not combine with nitrates.
L-arginine + Pycnogenol for erectile dysfunction (meta-analysis)
positive · Meta-analysis
Tian et al., 2023, Frontiers in Endocrinologyn=184Pooling 3 RCTs (n=184), the Pycnogenol + L-arginine combination improved the IIEF erectile-function score by ~8.9 points (95% CI 4.14–13.66) versus placebo, with gains in satisfaction and sexual desire. Testosterone did not change significantly.
Only 3 small trials, all in mild-to-moderate ED, with subjective questionnaire endpoints. Crucially, the benefit comes from a COMBINATION with Pycnogenol (a separate NO-active polyphenol) — these data cannot be attributed to arginine alone, and several constituent trials are tied to the Prelox/Pycnogenol commercial product.
Prelox (L-arginine aspartate + Pycnogenol) for erectile dysfunction
positive · RCT
Stanislavov et al., 2008, International Journal of Impotence Researchn=50Industry-fundedA representative crossover RCT (n=50) of the Prelox combination reported restored erectile function and roughly doubled intercourse frequency over one month, with increased sperm e-NOS and testosterone and no reported side effects. Frequently cited as evidence 'arginine works for ED.'
Small, one-month crossover testing a COMBINATION product (arginine plus Pycnogenol), so the arginine contribution is not isolable. This trial family is closely associated with the commercial Prelox/Pycnogenol product line — read the consistently glowing results with that in mind.
Pre-eclampsia risk (high-risk pregnancy)
Mechanism
Pre-eclampsia involves endothelial dysfunction and impaired NO-mediated vasodilation; supplying arginine substrate (with antioxidants) may support placental and maternal vascular function.
One strong single-center RCT (n=672) cut pre-eclampsia incidence to 12.7% (arginine + vitamins) vs 30.2% (placebo) in high-risk women. Promising, but the intervention bundled arginine with antioxidant vitamins, so the arginine-specific effect is uncertain, and it has not been broadly replicated.
Only studied in high-risk pregnancies, as a combination medical food, at one center. Supplementing in pregnancy must be done under obstetric supervision — not self-directed.
L-arginine + antioxidant vitamins for pre-eclampsia prevention
positive · RCT
Vadillo-Ortega et al., 2011, BMJn=672A genuinely strong trial (n=672, three arms). Pre-eclampsia developed in 30.2% of the placebo group, 22.5% with antioxidant vitamins alone, and 12.7% with L-arginine plus vitamins — a meaningful reduction in a high-risk population. The arginine arm clearly outperformed both comparators.
The intervention was L-arginine combined with antioxidant vitamins in a medical-food bar, so the arginine effect is partially confounded by the vitamins. Single-center (Mexico City), high-risk-only population — not a green light for routine arginine in pregnancy. Pregnant women should only supplement under obstetric supervision.
Exercise performance & 'the pump'
Mechanism
The marketing pitch is that arginine raises NO, dilates vessels, and improves blood flow and 'pump' during training. The pharmacokinetic problem undercuts this: oral arginine raises plasma arginine and NO markers poorly because of first-pass arginase metabolism.
Performance evidence in trained athletes is weak and inconsistent — acute oral arginine often fails to raise NO meaningfully, and ergogenic trials are mixed-to-null. The visible 'pump' is cosmetic vasodilation, not a strength or hypertrophy gain. Where a real NO ergogenic effect exists, citrulline malate (a small endurance/soreness benefit) is the better-supported choice.
Do not expect strength, power, or muscle-size gains. For an NO-mediated training effect, citrulline is better delivered than arginine.
Pharmacokinetics of oral citrulline vs arginine on nitric oxide
mixed · RCT
Schwedhelm et al., 2008, British Journal of Clinical Pharmacologyn=20The pharmacokinetic study that reframes the whole arginine category. Counterintuitively, oral L-citrulline raised plasma L-arginine more effectively than oral L-arginine itself — because arginine is heavily degraded by intestinal arginase before absorption, while citrulline bypasses it and is converted to arginine in the kidney. Honest takeaway: if the goal is to raise arginine/NO, citrulline is the better-delivered molecule.
Biomarker endpoints in healthy volunteers, not clinical outcomes. The result is the central reason to question oral arginine as an NO delivery vehicle — see our L-citrulline dossier for the matching analysis.
Peripheral arterial disease / walking capacity
Mechanism
The hope was that arginine would raise NO, improve leg blood flow, and extend pain-free walking distance in claudication.
It failed. In a 6-month RCT (n=133), L-arginine did not improve walking distance, did not raise NO synthesis, and actually performed slightly worse than placebo on walking and endothelial function. A clean negative — and a caution against long-term high-dose arginine for vascular disease.
Not supported for PAD/claudication. Chronic dosing may blunt endothelial function rather than help it.
L-arginine in peripheral arterial disease (intermittent claudication)
negative · RCT
Wilson et al., 2007, Circulationn=133Long-term L-arginine failed to improve walking distance in PAD — and did slightly worse than placebo (28.3% vs 11.5% improvement favored placebo, p=0.024). It did not raise nitric-oxide synthesis, and flow-mediated dilation fell in the arginine group while rising on placebo. The authors titled it 'No benefit and possible harm.'
Consistent with the broader pattern: chronic oral arginine does not reliably raise NO and may blunt endothelial function over time — likely because sustained dosing upregulates arginase and ADMA. Reinforces that citrulline is the better-evidenced NO strategy.
Honest-evidence ledger — 1 trial that didn’t move the needle
Surfacing failed trials alongside the positive evidence. Leaving them out would be marketing, not science.
VINTAGE MI — L-arginine after acute myocardial infarction
negative · RCT
Schulman et al., 2006, JAMAn=153The critical safety trial. L-arginine added to standard post-infarction therapy did not improve vascular stiffness or ejection fraction — and 6 of 70 participants (8.6%) in the L-arginine group died during the study versus none on placebo (p=0.01). The safety monitoring board halted enrollment. The authors concluded L-arginine should NOT be used after acute MI.
Single-center, modest size (n=153), and the mortality signal could be partly chance — but it is a hard, published harm signal in a vulnerable population. The directive stands: avoid L-arginine after a recent heart attack.
3 forms of Arginine compared
L-arginine (free base / HCl)
Poor systemic delivery — heavily degraded by intestinal and hepatic arginase before reaching the blood; raises plasma arginine LESS than oral citrulline
Best forBlood pressure support, mild ED (usually combined with Pycnogenol)The standard form. Bioavailability is the core weakness: first-pass arginase metabolism means much of the dose never raises systemic arginine. High doses (often needed for an effect) commonly cause GI upset. For an NO/arginine goal, L-citrulline is the better-delivered molecule.
heart4000–9000 mgArginine alpha-ketoglutarate (AAKG)
No better than plain L-arginine for raising NO; same first-pass arginase limitation applies
Best forPre-workout 'pump' productsA pre-workout staple marketed as a superior NO precursor. There is no good evidence AAKG outperforms plain arginine, and the underlying arginase bottleneck is unchanged. The pump is cosmetic vasodilation.
L-citrulline (the better-delivered alternative)
Well absorbed; bypasses intestinal arginase and raises plasma arginine MORE than oral arginine (Schwedhelm 2008)
Best forCross-reference — the smarter molecule when the goal is raising arginine/NONot a form of arginine, but the honest recommendation: if you want an arginine/NO effect (blood pressure, endurance, ED), L-citrulline delivers it more efficiently and with less GI upset. See our dedicated L-citrulline dossier.
Are you deficient? Symptoms, risk groups, lab tests
Arginine is a 'conditionally essential' amino acid — healthy adults synthesize enough (largely via the intestine-kidney citrulline route) and get more from protein-rich foods, so frank dietary deficiency is rare. It is supplemented pharmacologically for its nitric-oxide effect, not to correct a shortfall. Demand can rise in catabolic states (trauma, severe illness, rapid growth).
Side effects and drug interactions
Side effects
GI upset, bloating, diarrhea
Common · More common above ~9 g/day; some report it lower
The dose-limiting side effect. Because effective doses are high (often 4–9 g/day) and absorption is saturable, unabsorbed arginine causes osmotic GI symptoms. Markedly more common than with equivalent citrulline.
Gentler:l-citrulline
Hypotension / lightheadedness
Uncommon
Arginine's NO-mediated vasodilation can lower blood pressure, especially when stacked with antihypertensives, nitrates, or PDE-5 inhibitors.
Increased post-MI mortality
Severe
In the VINTAGE MI trial, post-heart-attack patients on L-arginine had significantly higher mortality (8.6% vs 0% placebo) and enrollment was stopped early. This is the single most important safety signal.
Possible herpes reactivation (theoretical)
Uncommon
Arginine is a substrate herpes viruses use for replication, and lysine competitively antagonizes it. The arginine-triggers-cold-sores idea rests on older in-vitro and mechanistic data plus case reports, not rigorous RCTs — but susceptible individuals sometimes report flares on high-dose arginine.
Drug interactions
Additive effect
PDE-5 inhibitors (sildenafil, tadalafil)nitrates (nitroglycerin, isosorbide)antihypertensivesArginine raises nitric oxide and is vasodilatory; stacking with nitrates or PDE-5 inhibitors can produce additive blood-pressure lowering.
Do not combine with prescription nitrates without medical supervision. Use caution alongside ED drugs or blood-pressure medication and watch for lightheadedness.
Combined-effect risk
potassium-sparing diureticspotassium supplementsACE inhibitors / ARBsL-arginine can modestly raise serum potassium; combined with potassium-retaining drugs this could add up.
Monitor potassium if combining, particularly in renal impairment.
Other critical caveats
- Do NOT take L-arginine after a recent heart attack. In the VINTAGE MI trial (Schulman 2006, JAMA), 6 of 70 post-MI patients on L-arginine died versus zero on placebo (p=0.01), and the trial was stopped early for safety. The authors recommended against its use post-MI.
- Oral arginine is a poor NO-delivery vehicle. Intestinal and hepatic arginase destroy much of the dose before it reaches the blood — Schwedhelm 2008 showed oral citrulline raises plasma arginine MORE than oral arginine itself. If you want an arginine/NO effect, citrulline is the better-evidenced choice.
- The 'pump' and performance pitch is weak. Acute oral arginine often fails to raise NO meaningfully in trained athletes, and ergogenic trials are inconsistent. The visible pump is cosmetic vasodilation, not a strength or muscle gain.
- Long-term high-dose arginine may not be benign for vascular disease: in the Wilson 2007 PAD trial it failed to help walking distance and slightly worsened endothelial function versus placebo.
- Do not combine with prescription nitrates, and use caution with PDE-5 inhibitors or blood-pressure medication — the vasodilatory effects are additive.
Frequently asked
Is L-arginine or L-citrulline better for nitric oxide?
Counterintuitively, L-citrulline. Oral arginine is heavily broken down by intestinal arginase before it's absorbed, so it raises blood arginine and nitric oxide poorly. Citrulline slips past that enzyme and is converted to arginine in the kidney — the Schwedhelm 2008 study found citrulline raised plasma arginine MORE than arginine itself, and with far less GI upset. If your goal is an arginine/NO effect, citrulline is the smarter molecule.Does L-arginine actually lower blood pressure?
Modestly, yes. Two meta-analyses found oral L-arginine (about 4–9 g/day) lowers systolic blood pressure by roughly 5–6 mmHg and diastolic by about 2.6 mmHg. The effect is real but small, disappears above ~9 g/day, and is a supportive adjunct — not a replacement for antihypertensive medication. Citrulline achieves a similar effect at lower doses.Can L-arginine help erectile dysfunction?
Mildly, but mostly in combination. The best evidence (a meta-analysis of 3 RCTs) is for L-arginine COMBINED with Pycnogenol in mild-to-moderate ED, not arginine alone, and the trials cluster around one commercial product. It works through the same nitric-oxide pathway as ED drugs but is clearly weaker than sildenafil-class medications and isn't validated for severe ED. Don't combine it with nitrates.Is L-arginine safe?
For most healthy adults at modest doses, generally — though high doses commonly cause diarrhea and bloating. The big exception is after a heart attack: in the VINTAGE MI trial, post-MI patients on L-arginine had significantly higher mortality than placebo and the study was halted early. Avoid it post-MI, use caution with blood-pressure drugs, nitrates, and PDE-5 inhibitors, and be aware of a theoretical herpes-reactivation risk in susceptible people.Will L-arginine give me a better pump or workout?
Probably not in any meaningful way. Because oral arginine raises nitric oxide poorly, acute pre-workout doses often fail to do much in trained athletes, and the performance trials are inconsistent. Any visible pump is cosmetic vasodilation, not a strength or muscle gain. If you want an NO-mediated training effect, citrulline malate has better (if still modest) evidence.
References
- 01Examine.com — Arginine
- 02Schulman et al., 2006 — VINTAGE MI: L-arginine after acute MI (JAMA)
- 03Shiraseb et al., 2022 — L-arginine and blood pressure dose-response meta-analysis (Advances in Nutrition)
- 04Wilson et al., 2007 — L-arginine in peripheral arterial disease (Circulation)
- 05Schwedhelm et al., 2008 — Citrulline vs arginine pharmacokinetics (Br J Clin Pharmacol)
Last reviewed2026-05-24